CVE-2022-47376

CVE-2022-47376 is a high-severity vulnerability in Bd Alaris Infusion Central with a CVSS 3.x base score of 7.3. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-522.

Key facts

Description

The Alaris Infusion Central software, versions 1.1 to 1.3.2, may contain a recoverable password after the installation. No patient health data is stored in the database, although some site installations may choose to store personal data.

Frequently asked questions

What is CVE-2022-47376?
The Alaris Infusion Central software, versions 1.1 to 1.3.2, may contain a recoverable password after the installation. No patient health data is stored in the database, although some site installations may choose to store personal data.
How severe is CVE-2022-47376?
CVE-2022-47376 has a CVSS 3.x base score of 7.3, rated high severity. It is exploitable over local access with low attack complexity, requires low privileges and no user interaction. Impact on confidentiality is high, integrity high, and availability low.
Is CVE-2022-47376 being actively exploited?
It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 0% (6th percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2022-47376?
CVE-2022-47376 affects Bd Alaris Infusion Central. See the affected-products list for the exact vulnerable versions.
How do I fix CVE-2022-47376?
Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its high severity, prioritise patching exposed systems.
When was CVE-2022-47376 published?
CVE-2022-47376 was published on 2023-06-13 and last updated on 2026-06-17.

References

Affected products (1)

Other CWE-522 (Insufficiently Protected Credentials) vulnerabilities

Browse all CWE-522 (Insufficiently Protected Credentials) vulnerabilities →